Literature DB >> 28043640

Alternate efflux pump mechanism may contribute to drug resistance in extensively drug-resistant isolates of Mycobacterium tuberculosis.

Akbar Kanji1, Rumina Hasan1, Ambreen Zaver1, Asho Ali1, Kehkashan Imtiaz1, Mussarat Ashraf1, Taane G Clark2, Ruth McNerney3, Samreen Shafiq1, Zahra Hasan4.   

Abstract

INTRODUCTION: Extensively drug-resistant tuberculosis (XDR-TB) has emerged as one of the biggest threats to public health and TB control programs worldwide. XDR-TB is caused by Mycobacterium tuberculosis (MTB) strains resistant to rifampin and isoniazid, as well as to a fluoroquinolone and to at least one injectable aminoglycoside. Drug resistance in MTB has primarily been associated with single nucleotide polymorphisms (SNPs) in particular genes. However, it has also been shown that efflux pumps may play a role in resistance of MTB. Upregulation of drug efflux pumps can decrease the intracellular concentration of drugs and reduce their efficacy.
METHODS: Whole genome sequencing was performed on 32 XDR-TB clinical isolates. Sequence data were used to investigate SNPs in efflux pump genes as compared with the H37Rv reference genome.
RESULTS: Of the XDR MTB strains, eight (21.62%) were wild type for rpsL, rrs (500 region), and gidB genes, but had non-synonymous (ns) SNPs (aspartic acid to histidine) in the drrA efflux pump gene at position 3273138. Three of eight (37.5%) XDR MTB strains, wild type for rpsL, rrs (500 region), gidB, and gyrB genes were phenotypically streptomycin sensitive and five (62.5%) XDR MTB strains were streptomycin resistant, while all XDR MTB strains, wild type for rpsL, rrs, gidB, and gyrB genes were resistant to fluoroquinolone (ofloxacin) and ethambutol. In addition, three XDR MTB strains wild type for rpsL, rrs, gidB, and drrA genes showed nsSNPs (isoleucine to valine) in the major facilitator superfamily, Rv1634 efflux pump gene at position 1839306.
CONCLUSION: Our data show an nsSNP in the drrA efflux pump gene that may result in upregulation of drug efflux mechanisms in MTB strains. It is therefore imperative to understand the mechanism of efflux and its role in drug resistance, which will enable the identification of new drug targets and development of new drug regimens to counteract the drug efflux mechanism of MTB.
Copyright © 2016.

Entities:  

Keywords:  Efflux pumps; MTB; XDR

Year:  2016        PMID: 28043640     DOI: 10.1016/j.ijmyco.2016.09.064

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  5 in total

1.  Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China.

Authors:  Y Hu; L Xu; Y L He; Y Pang; N Lu; J Liu; J Shen; D M Zhu; X Feng; Y W Wang; C Yang
Journal:  Biomed Res Int       Date:  2017-07-17       Impact factor: 3.411

Review 2.  The Tuberculosis Network European Trials Group (TBNET): new directions in the management of tuberculosis.

Authors:  Graham Bothamley
Journal:  Breathe (Sheff)       Date:  2017-09

3.  Characterisation of drug-resistant Mycobacterium tuberculosis mutations and transmission in Pakistan.

Authors:  Gary Napier; Anwar Sheed Khan; Abdul Jabbar; Muhammad Tahir Khan; Sajid Ali; Muhammad Qasim; Noor Mohammad; Rumina Hasan; Zahra Hasan; Susana Campino; Sajjad Ahmad; Baharullah Khattak; Simon J Waddell; Taj Ali Khan; Jody E Phelan; Taane G Clark
Journal:  Sci Rep       Date:  2022-05-11       Impact factor: 4.996

Review 4.  Diversity and evolution of drug resistance mechanisms in Mycobacterium tuberculosis.

Authors:  Mashael Al-Saeedi; Sahal Al-Hajoj
Journal:  Infect Drug Resist       Date:  2017-10-13       Impact factor: 4.003

5.  Cyclic di-GMP regulates Mycobacterium tuberculosis resistance to ethionamide.

Authors:  Hai-Nan Zhang; Zhao-Wei Xu; He-Wei Jiang; Fan-Lin Wu; Xiang He; Yin Liu; Shu-Juan Guo; Yang Li; Li-Jun Bi; Jiao-Yu Deng; Xian-En Zhang; Sheng-Ce Tao
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.